Literature DB >> 11720732

The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain.

J C Arnold1, A N Topple, P E Mallet, G E Hunt, I S McGregor.   

Abstract

Previous studies have suggested that cannabis-like drugs produce mainly aversive and anxiogenic effects in Wistar strain rats, but rewarding effects in Lewis strain rats. In the present study we compared Fos expression, body temperature effects and behavioral effects elicited by the cannabinoid CB(1) receptor agonist CP 55,940 in Lewis and Wistar rats. Both a moderate (50 microg/kg) and a high (250 microg/kg) dose level were used. The 250 microg/kg dose caused locomotor suppression, hypothermia and catalepsy in both strains, but with a significantly greater effect in Wistar rats. The 50 microg/kg dose provoked moderate hypothermia and locomotor suppression but in Wistar rats only. CP 55,940 caused significant Fos immunoreactivity in 24 out of 33 brain regions examined. The most dense expression was seen in the paraventricular nucleus of the hypothalamus, the islands of Calleja, the lateral septum (ventral), the central nucleus of the amygdala, the bed nucleus of the stria terminalis (lateral division) and the ventrolateral periaqueductal gray. Despite having a similar distribution of CP 55,940-induced Fos expression, Lewis rats showed less overall Fos expression than Wistars in nearly every brain region counted. This held equally true for anxiety-related brain structures (e.g. central nucleus of the amygdala, periaqueductal gray and the paraventricular nucleus of the hypothalamus) and reward-related sites (nucleus accumbens and pedunculopontine tegmental nucleus). In a further experiment, Wistar rats and Lewis rats did not differ in the amount of Fos immunoreactivity produced by cocaine (15 mg/kg). These results indicate that Lewis rats are less sensitive to the behavioral, physiological and neural effects of cannabinoids. The exact mechanism underlying this subsensitivity requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720732     DOI: 10.1016/s0006-8993(01)03127-4

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  19 in total

1.  Cannabinoid receptors are localized to noradrenergic axon terminals in the rat frontal cortex.

Authors:  Veronica C Oropeza; Kenneth Mackie; Elisabeth J Van Bockstaele
Journal:  Brain Res       Date:  2006-11-17       Impact factor: 3.252

Review 2.  Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences.

Authors:  J M McPartland; M Glass; R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-07-16       Impact factor: 8.739

3.  Repeated cannabinoid administration increases indices of noradrenergic activity in rats.

Authors:  M E Page; V C Oropeza; S E Sparks; Y Qian; A S Menko; E J Van Bockstaele
Journal:  Pharmacol Biochem Behav       Date:  2007-01-09       Impact factor: 3.533

4.  The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors.

Authors:  Alexandre A Steiner; Alla Y Molchanova; M Devrim Dogan; Shreya Patel; Erika Pétervári; Márta Balaskó; Samuel P Wanner; Justin Eales; Daniela L Oliveira; Narender R Gavva; M Camila Almeida; Miklós Székely; Andrej A Romanovsky
Journal:  J Physiol       Date:  2011-03-14       Impact factor: 5.182

5.  Chronic administration of THC prevents the behavioral effects of intermittent adolescent MDMA administration and attenuates MDMA-induced hyperthermia and neurotoxicity in rats.

Authors:  Erica Y Shen; Syed F Ali; Jerrold S Meyer
Journal:  Neuropharmacology       Date:  2011-07-13       Impact factor: 5.250

6.  Neural correlates of interactions between cannabidiol and Δ(9) -tetrahydrocannabinol in mice: implications for medical cannabis.

Authors:  S M Todd; J C Arnold
Journal:  Br J Pharmacol       Date:  2015-11-18       Impact factor: 8.739

7.  The CB1 receptor as an important mediator of hedonic reward processing.

Authors:  Chris M Friemel; Andreas Zimmer; Miriam Schneider
Journal:  Neuropsychopharmacology       Date:  2014-04-10       Impact factor: 7.853

8.  Cannabis reward: biased towards the fairer sex?

Authors:  I S McGregor; J C Arnold
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

Review 9.  Preclinical studies on the reinforcing effects of cannabinoids. A tribute to the scientific research of Dr. Steve Goldberg.

Authors:  Gianluigi Tanda
Journal:  Psychopharmacology (Berl)       Date:  2016-03-30       Impact factor: 4.530

Review 10.  The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism.

Authors:  Balapal S Basavarajappa
Journal:  Mini Rev Med Chem       Date:  2007-08       Impact factor: 3.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.